News

Improvements are seen after gene therapy for Leber congenital amaurosis.

According to a team of French investigators, every patient hospitalized with severe COVID-19 cases in their study had retinal and choroidal anomalies on indocyanine green angiography and optical coherence tomography images that were possibly related to the virus.

Bausch + Lomb and Clearside Biomedical announced Monday that the U.S. Food and Drug Administration has approved XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis.

Investigators have found that the early and late stages of uveal melanoma differ markedly.

All of the newborns in a recent study had ocular manifestations, the most common being periorbital edema and hemorrhagic conjunctivitis,

See the latest cartoon!

The development of involutional ptosis may be a multifactorial process, researchers have found.

According to the company, Susvimo is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

Three cases demonstrate value of new tools, technology for surgeons.

Fellowship recipient Christopher J. Kaler will explore functional links between BAP1 loss and aberrant activity of the nucleosome remodeling and deacetylase complex, which normally mediates embryonic lineage commitment and cellular differentiation.

According to investigators, aqueous humor analysis differentiated the tumors in patients.

The Delta variant still predominates in the US and UK, but the CDC mentions the AY variants as a concern, and suggested that it may be more contagious and more severe than the original COVID-19 strain.

There are times when physicians should be critical of scans.

In a study, investigators demonstrated the safety and therapeutic potential of clinically compliant iPSC-derived photoreceptor precursors as a cell replacement source for future clinical trials.

Demographics show high demand for solutions beyond eyeglasses.

Oyster Point Pharma, Inc. announced Monday that the U.S. FDA has granted approval of its TYRVAYA (varenicline solution) nasal spray 0.03 mg for the treatment of dry eye disease (DED), making it the first — and only — nasal spray approved for DED treatment in the U.S

A team of Israeli investigators sought to characterize breakthrough cases by evaluating health care workers with COVID-19 symptoms or who had been exposed to the virus.

Longtime clinician, researcher and head of the Ophthalmology Department at UCSF will succeed David W. Parke II, MD, at Academy helm.

Techniques, technologies minimize complications and guide counseling, care.

New data finds that preoperative ptosis occurs commonly and more often in patients with reactive blepharospasm or enophthalmos.

The FDA will decide whether to authorize the boosters based off the advisory panel's recommendations.

A team of investigators at Cleveland Clinic Abu Dhabi studied patients who presented with ocular adverse events within 15 days after the first of 2 doses of the inactivated COVID-19 vaccine Sinopharm.

Ocular herpes infection is a leading cause of infectious blindness and can lead to lethal brain infections. Using genetically modified mice models, investigators uncovered the importance of mTORC2 in activation of innate- and virus-adaptive immunity during ocular HSV-1 infection.

Investigators find that long-term ocular complications require further observation.

To mark World Sight Day, Nanodropper Inc. has developed a pay-it-forward Nanodropper Adaptor program, allowing anyone to donate devices to a pool for distribution to patients in need.

As the world comes together to shine a global spotlight on blindness and vision impairment on World Sight Day, several global organizations and companies are stepping up to increase awareness of eye health, including the importance of regular examinations by an ophthalmologist or optometrist.

Papilledema with back pain suggests spine lesion.

Oxurion NV announced Wednesday the first patient to be dosed in the INTEGRAL phase 2 clinical study evaluating THR-687 as a treatment for patients with DME.